David R. Liu
Known title: 10% OwnerCIK: 0001664439
David R. Liu's purchase track record
David R. Liu has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/23/2025 | PRME | $98K | +131.0% | +71.3% | +14.2% |
| 6/11/2025 | PRME | $65K | +154.3% | +183.0% | +14.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PRME | ▲ Buy | Open Market | 21,000 | $53K | 6/30/2025 | View on chart |
| PRME | ▲ Buy | Open Market | 21,000 | $45K | 6/23/2025 | View on chart |
| PRME | ▲ Buy | Open Market | 21,000 | $31K | 6/16/2025 | View on chart |
| PRME | ▲ Buy | Open Market | 21,000 | $34K | 6/11/2025 | View on chart |
| PRME | ▼ Sell | Gift | 1,000,000 | $0 | 7/21/2023 | View on chart |
| PRME | ▼ Sell | Other | 321,665 | — | 10/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Prime Medicine stock surges after FDA clears IND for PM647
Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.
Prime Medicine stock surges after FDA clears IND for PM647. Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.